|Awarded On||February 18, 2015|
|Title||SRC-2 driven "Metabolic Switch" in metastatic prostate cancer- Prognostic and Therapeutic implications|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Arun Sreekumar|
Prostate cancer is the second most common epithelial cancer and one of the leading causes of cancer related death for men. In order to better understand the reasons for cancer development, researchers during the last decade decoded the entire genetic makeup of prostate cancer patients to identify ‘cancer-specific’ genes. One of the genes to be identified was ‘Steroid Receptor Coactivator-2’ (SRC-2). SRC-2 gene was found to be increased in 8% of primary tumors (cancer-confined to the prostate) and 37% of metastatic tumors (cancer-spread to other organs). Strikingly, patients with primary tumor who had increased SRC-2 expression developed early disease recurrence, suggesting SRC-2 expression m...